CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.
Overview
Genetic engineering and weight-loss innovation have become focal points for modern healthcare investors. Choosing between CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) depends on your appetite for risk and your belief in their distinct medical breakthroughs.
CRISPR Therapeutics uses gene-editing technology to address diseases at their genetic source, while Viking focuses on metabolic conditions such as obesity that affect millions globally. Both companies represent high-potential opportunities within the biotechnology space, though they currently sit at very different stages of their respective commercial journeys.
Details
CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company recently achieved a major milestone with the commercial launch of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. It operates under a strategic collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages global manufacturing and commercialization. Customer concentration like this adds a layer of risk to the business, as CRISPR Therapeutics relies on this partner for 60% of its profits and losses.
Source
Originally published at www.fool.com.